Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
103 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Pollen Allergy - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Pollen Allergy - Pipeline Review, H2 2014', provides an overview of the Pollen Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pollen Allergy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pollen Allergy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pollen Allergy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Pollen Allergy Overview 10 Therapeutics Development 11 Pipeline Products for Pollen Allergy - Overview 11 Pipeline Products for Pollen Allergy - Comparative Analysis 12 Pollen Allergy - Therapeutics under Development by Companies 13 Pollen Allergy - Therapeutics under Investigation by Universities/Institutes 15 Pollen Allergy - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Pollen Allergy - Products under Development by Companies 19 Pollen Allergy - Products under Investigation by Universities/Institutes 21 Pollen Allergy - Companies Involved in Therapeutics Development 22 ALK-Abello A/S 22 Allergopharma Joachim Ganzer KG 23 Allergy Therapeutics plc 24 Anergis SA 25 Biomay AG 26 BioTech Tools s.a. 27 Circassia Pharmaceuticals plc 28 HAL Allergy BV 29 Immunomic Therapeutics, Inc. 30 Japan Tobacco Inc. 31 Laboratorios LETI S.L. 32 REGiMMUNE Corporation 33 Roxall Medizin GmbH 34 Stallergenes S.A. 35 Pollen Allergy - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Combination Products 37 Assessment by Target 38 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Drug Profiles 43 ALK Birch Pollen Vaccine - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 AllerG - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Allergen Extract Of Phleum Pratense - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 AllerJ - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 AllerT - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Avanz Phleum Pratense - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Birch-SPIRE - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 BM-31 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 BM-32 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 clustoid wiesenlieschgras - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Drug for Birch Pollen Allergy - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Drug for Japanese Cedar Pollen Allergy - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Drugs for Cedar Pollen Allergy - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 gpASIT + TM - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 grass allergy vaccine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Grass-SPIRE - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Japanese cedar hypoallergenic vaccine - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 JCC-LAMP-Vax - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 JRC-LAMP-Vax - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 MC-LAMP-Vax - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Multi-LAMP-Vax - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 PL-102 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Pollinex Quattro Grass - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Pollinex Quattro Japanese Cedar - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Pollinex Quattro Tree - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 rBet v1 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 rBet v1-FV - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 RGI-1001 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 timothy grass pollen allergen extract - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 TO-206 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Vaccine for Cedar Pollen Allergy - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Vaccine for Cedar Pollen Allergy - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Vaccine for Pollen Allergy - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Pollen Allergy - Recent Pipeline Updates 87 Pollen Allergy - Dormant Projects 93 Pollen Allergy - Discontinued Products 95 Pollen Allergy - Product Development Milestones 96 Featured News & Press Releases 96 Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT 96 Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT 96 Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT 97 Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK 97 Feb 27, 2014: Phase IIb Results of Anergis� Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego 98 Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study 98 Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) 99 Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32 99 Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK 100 Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet 100 Appendix 102 Methodology 102 Coverage 102 Secondary Research 102 Primary Research 102 Expert Panel Validation 102 Contact Us 103 Disclaimer 103
List of Tables Number of Products under Development for Pollen Allergy, H2 2014 11 Number of Products under Development for Pollen Allergy - Comparative Analysis, H2 2014 12 Number of Products under Development by Companies, H2 2014 14 Number of Products under Investigation by Universities/Institutes, H2 2014 15 Comparative Analysis by Late Stage Development, H2 2014 16 Comparative Analysis by Clinical Stage Development, H2 2014 17 Comparative Analysis by Early Stage Development, H2 2014 18 Products under Development by Companies, H2 2014 19 Products under Development by Companies, H2 2014 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2014 21 Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2014 22 Pollen Allergy - Pipeline by Allergopharma Joachim Ganzer KG, H2 2014 23 Pollen Allergy - Pipeline by Allergy Therapeutics plc, H2 2014 24 Pollen Allergy - Pipeline by Anergis SA, H2 2014 25 Pollen Allergy - Pipeline by Biomay AG, H2 2014 26 Pollen Allergy - Pipeline by BioTech Tools s.a., H2 2014 27 Pollen Allergy - Pipeline by Circassia Pharmaceuticals plc, H2 2014 28 Pollen Allergy - Pipeline by HAL Allergy BV, H2 2014 29 Pollen Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2014 30 Pollen Allergy - Pipeline by Japan Tobacco Inc., H2 2014 31 Pollen Allergy - Pipeline by Laboratorios LETI S.L., H2 2014 32 Pollen Allergy - Pipeline by REGiMMUNE Corporation, H2 2014 33 Pollen Allergy - Pipeline by Roxall Medizin GmbH, H2 2014 34 Pollen Allergy - Pipeline by Stallergenes S.A., H2 2014 35 Assessment by Monotherapy Products, H2 2014 36 Assessment by Combination Products, H2 2014 37 Number of Products by Stage and Target, H2 2014 38 Number of Products by Stage and Route of Administration, H2 2014 40 Number of Products by Stage and Molecule Type, H2 2014 42 Pollen Allergy Therapeutics - Recent Pipeline Updates, H2 2014 87 Pollen Allergy - Dormant Projects, H2 2014 93 Pollen Allergy - Dormant Projects (Contd..1), H2 2014 94 Pollen Allergy - Discontinued Products, H2 2014 95
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
